At MIT, synthetic biology and systems biology researchers, including James J. Collins, use AI-driven quantitative modeling to program cells with novel therapeutic properties, targeting complex challenges such as Ebola, Zika, COVID-19, and antibiotic-resistant bacteria. Their approach integrates deep learning with biological networks to identify potential drug candidates more efficiently.
Collaborations among experts in artificial intelligence, biological engineering, and machine learning have been crucial, exemplified by partnerships at MIT’s Jameel Clinic for Machine Learning in Health. These interdisciplinary efforts aim to transform therapeutic design by applying AI to biological systems modeling and drug discovery.
Source & further reading
3 Questions: Using AI to accelerate the discovery and design of therapeutic drugs ↗Source published 2026-02-04. This report was prepared with AI assistance from the linked primary-source material. Claims and limitations should be checked against the original announcement or research.